ERCC1 expression predicts efficacy in patients with non-small cell lung cancer or head and neck squamous cell carcinoma, who have received platinum-based concurrent chemoradiotherapy; meanwhile, patients with low ERCC1 expression often show better treatment response and survival [20, 21]. Here, ERCC1 is linked to non-small cell lung carcinoma.